Cargando…
Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution
BACKGROUND: Interest in carbapenems has been rising in the last few years due to the emergence of drug resistant tuberculosis. Ertapenem (ETP), given once a day parenteral, and faropenem (FAR), oral, have a better administration profile than meropenem (MEM), imipenem (IPM) and doripenem (DOR). The a...
Autores principales: | Gonzalo, Ximena, Satta, Giovanni, Ortiz Canseco, Julio, McHugh, Timothy D., Drobniewski, Francis |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457350/ https://www.ncbi.nlm.nih.gov/pubmed/32867678 http://dx.doi.org/10.1186/s12866-020-01954-w |
Ejemplares similares
-
2447. Ertapenem and Faropenem for the Treatment of Drug-Resistant Tuberculosis
por: Satta, Giovanni, et al.
Publicado: (2018) -
Tedizolid, Faropenem, and Moxifloxacin Combination With Potential Activity Against Nonreplicating Mycobacterium tuberculosis
por: Srivastava, Shashikant, et al.
Publicado: (2021) -
Mycobacterium tuberculosis sterilizing activity of faropenem, pyrazinamide and linezolid combination and failure to shorten the therapy duration
por: Gumbo, Tawanda, et al.
Publicado: (2021) -
Molecular Epidemiology of Mycobacterium tuberculosis, Buenos Aires, Argentina
por: Gonzalo, Ximena, et al.
Publicado: (2011) -
Emergence of phenotypic and genotypic antimicrobial resistance in Mycobacterium tuberculosis
por: Kloprogge, Frank, et al.
Publicado: (2022)